Florent Malard

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4058909/publications.pdf

Version: 2024-02-01

97	4,261	101543	128289
papers	citations	36 h-index	60 g-index

99	99	99	6086
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2016, 51, 906-912.	2.4	364
2	Acute lymphoblastic leukaemia. Lancet, The, 2020, 395, 1146-1162.	13.7	343
3	Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectivesâ€"a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2015, 50, 781-789.	2.4	294
4	Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal, 2019, 9, 44.	6.2	175
5	COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplantation, 2020, 55, 2180-2184.	2.4	138
6	Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus -host disease prophylaxis in haploidentical transplant. Haematologica, 2017, 102, 401-410.	3.5	109
7	Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer Journal, 2021, 11, 142.	6.2	106
8	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplantation, 2020, 55, 1114-1125.	2.4	97
9	Introduction to host microbiome symbiosis in health and disease. Mucosal Immunology, 2021, 14, 547-554.	6.0	95
10	Production of BMP4 by endothelial cells is crucial for endogenous thymic regeneration. Science Immunology, 2018, 3, .	11.9	93
11	Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. Haematologica, 2019, 104, 1682-1688.	3.5	91
12	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2020, 105, 1507-1516.	3.5	91
13	Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia, 2019, 33, 2343-2357.	7.2	90
14	Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation: Time To T Up the Thymus. Journal of Immunology, 2017, 198, 40-46.	0.8	87
15	IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. Journal of Clinical Investigation, 2019, 129, 1910-1925.	8.2	85
16	Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. Haematologica, 2015, 100, 859-869.	3.5	80
17	IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect. Leukemia, 2013, 27, 1527-1537.	7.2	77
18	Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplantation, 2019, 54, 1815-1826.	2.4	75

#	Article	IF	Citations
19	Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia, 2020, 34, 1229-1240.	7.2	73
20	Impact of Cyclosporine-A Concentration on the Incidence of Severe Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 28-34.	2.0	70
21	Plasmacytoid dendritic cell biology and itsÂrole in immuneâ€mediated diseases. Clinical and Translational Immunology, 2020, 9, e1139.	3.8	70
22	Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. Leukemia, 2011, 25, 932-938.	7.2	64
23	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplantation, 2020, 55, 485-495.	2.4	61
24	Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 1013-1021.	2.0	59
25	Biomarkers in chronic graft-versus-host disease: quo vadis?. Bone Marrow Transplantation, 2018, 53, 832-837.	2.4	55
26	Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival. Blood, 2016, 127, 1828-1835.	1.4	52
27	Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation. JACC: CardioOncology, 2021, 3, 250-259.	4.0	48
28	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia, 2019, 33, 2767-2778.	7.2	47
29	Plasmacytoid dendritic cells and Th17 immune response contribution in gastrointestinal acute graft-versus-host disease. Leukemia, 2012, 26, 1471-1474.	7.2	46
30	Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML). Leukemia, 2015, 29, 2375-2381.	7.2	43
31	Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia. Haematologica, 2017, 102, 184-191.	3.5	43
32	Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide. Biology of Blood and Marrow Transplantation, 2012, 18, 314-317.	2.0	42
33	Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1407-1415.	2.0	42
34	Continuous Reduced Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Institutionâ€™s Three Decade Experience. Biology of Blood and Marrow Transplantation, 2014, 20, 1217-1223.	2.0	39
35	Management of patients with multiple myeloma during the COVID-19 pandemic. Lancet Haematology,the, 2020, 7, e435-e437.	4.6	39
36	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 278-284.	2.0	38

#	Article	IF	Citations
37	Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients. Nature Communications, 2021, 12, 3084.	12.8	38
38	High gastrointestinal microbial diversity and clinical outcome in graft-versus-host disease patients. Bone Marrow Transplantation, 2018, 53, 1493-1497.	2.4	37
39	Comprehensive Review of AL amyloidosis: some practical recommendations. Blood Cancer Journal, 2021, 11, 97.	6.2	37
40	Interferon-Alpha Promotes Th1 Response and Epithelial Apoptosis via Inflammasome Activation in Human Intestinal Mucosa. Cellular and Molecular Gastroenterology and Hepatology, 2017, 3, 72-81.	4.5	34
41	Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. Blood, 2020, 136, 1903-1906.	1.4	34
42	High-Dose Total Body Irradiation and Myeloablative Conditioning before Allogeneic Hematopoietic Cell Transplantation: Time to Rethink?. Biology of Blood and Marrow Transplantation, 2015, 21, 620-624.	2.0	33
43	18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study. Bone Marrow Transplantation, 2014, 49, 131-137.	2.4	30
44	New Insight for the Diagnosis of Gastrointestinal Acute Graft-versus-Host Disease. Mediators of Inflammation, 2014, 2014, 1-9.	3.0	30
45	Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. Blood, 2017, 130, 2186-2195.	1.4	30
46	Reducedâ€toxicity conditioning with fludarabine, onceâ€daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial. Cancer, 2015, 121, 562-569.	4.1	28
47	Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1471-1475.	2.0	28
48	Features of Toxoplasma gondii reactivation after allogeneic hematopoietic stem-cell transplantation in a high seroprevalence setting. Bone Marrow Transplantation, 2020, 55, 93-99.	2.4	27
49	Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2015, 50, 1574-1577.	2.4	23
50	Allogeneic transplant forFLT3-ITDmutated AML: a focus onFLT3inhibitors before, during, and after transplant. Therapeutic Advances in Hematology, 2019, 10, 204062071988266.	2.5	22
51	Translational opportunities for targeting the Th17 axis in acute graft-vs.-host disease. Mucosal Immunology, 2016, 9, 299-308.	6.0	20
52	Increased plasmacytoid dendritic cells and RORÎ³t-expressing immune effectors in cutaneous acute graft-versus-host disease. Journal of Leukocyte Biology, 2013, 94, 1337-1343.	3.3	19
53	CD34 -selected stem cell â€œBoostâ€•for poor graft function after allogeneic hematopoietic stem cell transplantation. Current Research in Translational Medicine, 2019, 67, 112-114.	1.8	19
54	Pre-emptive rituximab treatment for Epsteinâ€“Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes. Bone Marrow Transplantation, 2020, 55, 586-594.	2.4	19

#	Article	IF	Citations
55	Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer Journal, 2022, 12, 47.	6.2	19
56	Infectious complications after postâ€transplantation cyclophosphamide and antiâ€thymocyte globulinâ€based haploidentical stem cell transplantation. British Journal of Haematology, 2019, 187, e64-e68.	2.5	18
57	Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. Journal of Hematology and Oncology, 2018, 11, 127.	17.0	17
58	Impact of cyclosporine A concentration on acute graftâ€versâ€host disease incidence after haploidentical hematopoietic cell transplantation. European Journal of Haematology, 2019, 103, 10-17.	2.2	17
59	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplantation, 2020, 55, 1525-1532.	2.4	17
60	Daratumumab prevents programmed death ligandâ€1 expression on antigenâ€presenting cells in de novo multiple myeloma. Cancer Medicine, 2020, 9, 2077-2084.	2.8	17
61	Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies. Bone Marrow Transplantation, 2020, 55, 763-772.	2.4	16
62	Old dog, new trick: Trivalent arsenic as an immunomodulatory drug. British Journal of Pharmacology, 2020, 177, 2199-2214.	5.4	16
63	Early detection of acute graftâ€versusâ€host disease by wireless capsule endoscopy and probeâ€based confocal laser endomicroscopy: results of a pilot study. United European Gastroenterology Journal, 2014, 2, 206-215.	3.8	15
64	Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis. Cancer Treatment Reviews, 2017, 52, 41-47.	7.7	15
65	Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia. Bone Marrow Transplantation, 2020, 55, 452-460.	2.4	12
66	Arsenic trioxide induces regulatory functions of plasmacytoid dendritic cells through interferon-inhibition. Acta Pharmaceutica Sinica B, 2020, 10, 1061-1072.	12.0	12
67	Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 377-382.	0.4	10
68	Impact of donor hematopoietic cells mobilized with G-CSF and plerixafor on murine acute graft-versus-host-disease. Cytotherapy, 2015, 17, 948-955.	0.7	9
69	Antithymocyte Globulin for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2017, 35, 3993-3995.	1.6	9
70	Highâ€dose postâ€transplant cyclophosphamide impairs Î³Î´ Tâ€cell reconstitution after haploidentical haematopoietic stem cell transplantation using lowâ€dose antithymocyte globulin and peripheral blood stem cell graft. Clinical and Translational Immunology, 2020, 9, e1171.	3.8	9
71	Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience. Leukemia and Lymphoma, 2021, 62, 419-427.	1.3	9
72	Impact of gut fungal and bacterial communities on the outcome of allogeneic hematopoietic cell transplantation. Mucosal Immunology, 2021, 14, 1127-1132.	6.0	9

#	Article	IF	Citations
73	The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial. Blood, 2018, 132, 1444-1444.	1.4	9
74	Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: A single-center experience. Cytotherapy, 2020, 22, 445-449.	0.7	8
75	TFH cells in systemic sclerosis. Journal of Translational Medicine, 2021, 19, 375.	4.4	8
76	Venetoclax does not impair activated T-cell proliferation. Bone Marrow Transplantation, 2021, 56, 1740-1742.	2.4	7
77	Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 791-796.	0.4	6
78	Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases: Considerations and Perspectives on Behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT. Frontiers in Oncology, 2021, 11, 722436.	2.8	6
79	Allogeneic haematopoietic cell transplantation for myelofibrosis: a realâ€life perspective. British Journal of Haematology, 2021, 195, 495-506.	2.5	5
80	Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program. Blood, 2020, 136, 15-15.	1.4	5
81	Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients?. Current Research in Translational Medicine, 2021, 69, 103273.	1.8	4
82	A novel mouse model of acute graft-versus-host disease based on chemotherapy conditioning and G-CSF mobilized graft. Bone Marrow Transplantation, 2020, 55, 570-577.	2.4	3
83	Letâ€™s reconstitute microbiota diversity. Blood, 2021, 137, 1442-1444.	1.4	3
84	Resolution of bortezomib-associated chalazia/blepharitis after switch to ixazomib: A case report. Current Research in Translational Medicine, 2021, 69, 103283.	1.8	3
85	Evaluation of Infectious Complications after Haploidentical Stem Cell Transplantation in Adult Patients with Hematologic Malignancies. Blood, 2017, 130, 664-664.	1.4	3
86	Gut microbiota alteration during allogeneic haematopoietic cell transplantation: what can we do?. British Journal of Haematology, 2020, 188, 351-353.	2.5	2
87	Outcome of allogeneic hematopoietic stem cell transplant recipients admitted to the intensive care unit with a focus on haploidentical graft and sequential conditioning regimen: results of a retrospective study. Annals of Hematology, 2021, 100, 2787-2797.	1.8	2
88	Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better. Clinical Hematology International, 2020, 2, 92.	1.7	2
89	Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient. Current Research in Translational Medicine, 2022, 70, 103329.	1.8	2
90	Cutaneous lupus with Kikuchi disease-like inflammatory pattern associated with myelodysplastic syndrome. Rheumatology, 2019, 58, 554-556.	1.9	1

#	Article	IF	Citations
91	Increasing Donor Options in Allogenic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2021, 39, 1951-1954.	1.6	1
92	COVID-19 in the context of autologous hematopoietic stem cell transplantation for a patient with autoimmune disease. Current Research in Translational Medicine, 2022, 70, 103332.	1.8	1
93	Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia. British Journal of Haematology, 2022, 198, 780-784.	2.5	1
94	Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience. Leukemia and Lymphoma, 2022, 63, 443-449.	1.3	0
95	Achievement of High Concentration of Cyclosporine-a Is Associated with a Low Incidence of Acute Graft-Versus-Host Disease after Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Graft. Blood, 2018, 132, 4565-4565.	1.4	0
96	Arsenic Trioxide Induces Apoptosis and Regulatory Functions of Plasmacytoid Dendritic Cells. Blood, 2018, 132, 514-514.	1.4	0
97	Low incidence of hyperacute graftâ€versusâ€host disease (<scp>GVHD)</scp> with effective <scp>GVHD</scp> prophylaxis based on antiâ€thymocyte globulin. British Journal of Haematology, 2022, , .	2.5	0